Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Acacia Pharma Group    ACPH   GB00BYWF9Y76

ACACIA PHARMA GROUP

(ACPH)
  Report
Delayed Quote. Delayed Euronext Bruxelles - 02/26 10:02:18 am
2.95 EUR   +1.37%
01/27ACACIA PHARMA : wins BEL Small Company of the Year 2019
AQ
01/24ACACIA PHARMA : wins BEL Small Company of the Year 2019
AQ
01/14TR-1 : Standard form for notification of major holdings
AQ
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
02/20/2020 02/21/2020 02/24/2020 02/25/2020 02/26/2020 Date
2.855(c) 2.91(c) 2.74(c) 2.91(c) 2.95 Last
174 885 175 371 399 660 458 323 628 266 Volume
-3.06% +1.93% -5.84% +6.20% +1.37% Change
More quotes
Financials (GBP)
Sales 2019 -
EBIT 2019 -23,1 M
Net income 2019 -23,6 M
Finance 2019 5,20 M
Yield 2019 -
Sales 2020 1,76 M
EBIT 2020 -27,3 M
Net income 2020 -28,0 M
Debt 2020 36,0 M
Yield 2020 -
P/E ratio 2019 -5,53x
P/E ratio 2020 -6,09x
EV / Sales2019 -
EV / Sales2020 109x
Capitalization 156 M
More Financials
Company
Acacia Pharma Group specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2018, the group had a portfolio of 2 products, including APD403 in... 
Sector
Pharmaceuticals
Calendar
09/04Earnings Release
More about the company
Latest news on ACACIA PHARMA GROUP
01/27ACACIA PHARMA : wins BEL Small Company of the Year 2019
AQ
01/24ACACIA PHARMA : wins BEL Small Company of the Year 2019
AQ
01/14TR-1 : Standard form for notification of major holdings
AQ
01/13ACACIA PHARMA : Issue of Equity on Share Subscription and Licensing agreement Wi..
AQ
01/13Acacia Pharma enters into strategic in-licensing, investment and loan transac..
AQ
01/13Cosmo sub-licenses its ByFavo US rights to Acacia Pharma, takes an initial 14..
AQ
01/13ACACIA PHARMA : nbsp;announces planned CFO succession
PU
01/13ACACIA PHARMA : announces planned CFO succession
AQ
01/10ACACIA PHARMA : enters into strategic in-licensing, investment and loan transact..
AQ
01/02TR-1 : Standard form for notification of major holdings
AQ
2019TR-1 : Standard form for notification of major holdings
AQ
2019ACACIA PHARMA GROUP : Crossing thresholds
CO
2019TR-1 : Standard form for notification of major holdings
AQ
2019ACACIA PHARMA GROUP : Crossing thresholds
CO
2019ACACIA PHARMA GROUP : Crossing thresholds
CO
More news
News in other languages on ACACIA PHARMA GROUP
01/10Bourse Zurich: le SMI termine sur une note légèrement négative
01/10Bourse Zurich: le SMI toujours dans le vert, en desssous des 10'700 points
01/10Bourse Zurich: ouverture attendue en hausse, la propension au risque se renfo..
01/10Cosmo conclut un accord de licence avec Acacia Pharma, entre au capital
01/10COSMO : Acacia wird US-Lizenzpartner für Byfavo
More news
Sector news : Pharmaceuticals - NEC
03:22aNEW CHINESE BILLIONAIRES OUTPACE U.S : Hurun
RE
02/25Soybeans Claw Back Some Coronavirus Losses
DJ
02/25Apple, J&J to study if Apple Watch app leads to lower stroke risk
RE
02/25DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/25ALLERGAN : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart ACACIA PHARMA GROUP
Duration : Period :
Acacia Pharma Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACACIA PHARMA GROUP
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price
Last Close Price 2,91  
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Michael Bolinder Chief Executive Officer & Executive Director
Patrick Volkert Vink Non-Executive Chairman
Christine Helen Soden CFO, Secretary & Executive Director
Gabriel Fox Chief Medical Officer
Scott A. Byrd Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ACACIA PHARMA GROUP37.91%202
JOHNSON & JOHNSON0.03%381 112
ROCHE HOLDING AG10.13%287 430
MERCK AND COMPANY-11.74%204 366
NOVARTIS2.72%201 414
PFIZER-11.51%187 773